



Uppsala 27 November 2019

PRESS RELEASE

Correction: The CEO of Oasmia buys subscription rights in the ongoing rights issue

In a previous press release today, November 27, it was stated that Oasmia Pharmaceutical AB's CEO Sven Rohmann bought 978,944 subscription rights in the company. The correct number should be 900,000 subscription rights. The error occurred due to incorrectly summed data by Sven Rohmann's bank.

For more information:

Urban Ekelund, IR Manager Oasmia
E-mail: IR@oasmia.com

About Oasmia Pharmaceutical AB

Oasmia Pharmaceutical AB develops, manufactures and markets new generations of drugs in the field of human and veterinary oncology. The company's product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company's product development is based on its proprietary in-house research and company patents. Oasmia is listed on Nasdaq Stockholm (OASM) and Frankfurt Stock Exchange (OMAX.GR).